Using a combined approach of experimental measurements and molecular dynamics simulations, in this contribution we aim at elucidating the role of FKBP12 in α-syn aggregation kinetics and aggregate morphology suggesting at the same time a possible therapeutic agent, the synthetic ElteN378 FKBP12 inhibitor16, in PD neuropathies. The gene discussed is FKBP1A; the disease is Parkinson disease.